Costco's Protein Boom: GLP-1 Trend Boosts Demand, But Whey Shortage Looms

What happened

Costco is experiencing surging demand for protein-packed foods, a trend management attributes to the rising popularity of GLP-1 drugs that encourage higher protein intake to preserve muscle mass. This demand driver provides a near-term tailwind for same-store sales and reinforces Costco's value proposition in bulk staples, but it also introduces a new risk: a looming whey protein shortage that could pressure supply costs and potentially force price adjustments. The DeepValue thesis already prices Costco at a premium (51.7x P/E) with limited margin for error, relying on sustained comps and membership renewal. While the protein trend could help sustain comps near 5-7%, the supply constraint adds an incremental cost headwind that management must navigate without eroding the low-price model. Overall, the narrative remains 'priced for perfection,' with the protein story offering modest support but insufficient to justify entry above $900 given the existing valuation risk.

Implication

The GLP-1-driven protein demand is a genuine consumption shift that benefits Costco’s bulk protein sales and could help comps hold at the high end of expectations. However, the whey shortage introduces a cost risk that could compress gross margins if Costco absorbs price increases or forces shelf-price adjustments that dilute its value image. The DeepValue framework already flags that the stock’s premium multiple leaves no room for error, and the supply-side pressure is an incremental negative that the market has not yet priced. For long-term investors, the protein trend is a positive secular signal, but until the stock corrects to ~$900 or the supply outlook clears, the risk of a comp miss or margin squeeze outweighs the reward. Maintain a WAIT rating with a bias to add on weakness, monitoring monthly comps and any margin commentary in upcoming earnings calls.

Thesis delta

The Business Insider article introduces a new demand tailwind (GLP-1 protein demand) that could support Costco’s comps, but also a supply headwind (whey shortage) that could pressure margins. This adds a moderately positive bias to the near-term sales outlook but introduces a cost risk that partially offsets the benefit. The overall thesis shifts from purely valuation-sensitive to balanced between a potential demand boost and a new margin threat, keeping the wait-and-see stance intact.